KR20070119710A - Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정 - Google Patents

Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정 Download PDF

Info

Publication number
KR20070119710A
KR20070119710A KR1020077024730A KR20077024730A KR20070119710A KR 20070119710 A KR20070119710 A KR 20070119710A KR 1020077024730 A KR1020077024730 A KR 1020077024730A KR 20077024730 A KR20077024730 A KR 20077024730A KR 20070119710 A KR20070119710 A KR 20070119710A
Authority
KR
South Korea
Prior art keywords
leu
growth factor
hepatocyte growth
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077024730A
Other languages
English (en)
Korean (ko)
Inventor
미카엘 데트마
겐타로 가지야
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Publication of KR20070119710A publication Critical patent/KR20070119710A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
KR1020077024730A 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정 Withdrawn KR20070119710A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66746305P 2005-03-31 2005-03-31
US60/667,463 2005-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137019978A Division KR20130114763A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정

Publications (1)

Publication Number Publication Date
KR20070119710A true KR20070119710A (ko) 2007-12-20

Family

ID=36638370

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077024730A Withdrawn KR20070119710A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
KR1020137019978A Abandoned KR20130114763A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
KR1020147011245A Ceased KR20140068234A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137019978A Abandoned KR20130114763A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
KR1020147011245A Ceased KR20140068234A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정

Country Status (10)

Country Link
US (4) US20070010443A1 (enExample)
EP (2) EP2674165B1 (enExample)
JP (5) JP5313660B2 (enExample)
KR (3) KR20070119710A (enExample)
CN (2) CN101189023B (enExample)
DK (1) DK1863519T3 (enExample)
ES (1) ES2440953T3 (enExample)
PL (1) PL1863519T3 (enExample)
TW (1) TWI362940B (enExample)
WO (1) WO2006105511A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
JP4171061B2 (ja) 2005-02-09 2008-10-22 アーキュール，インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
JP5313660B2 (ja) * 2005-03-31 2013-10-09 ザ ジェネラル ホスピタル コーポレイション Ｈｇｆ／ｈｇｆｒ活性の観察と調節
WO2007013603A1 (ja) 2005-07-28 2007-02-01 Anges Mg, Inc. リンパ管新生促進剤
US20090169473A1 (en) * 2005-10-24 2009-07-02 Fujifilm Ri Pharma Co., Ltd. Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor
EP2173748B1 (en) 2007-06-22 2011-08-31 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
JP2010530885A (ja) 2007-06-22 2010-09-16 アークル インコーポレイテッド キナゾリノン化合物およびその使用方法
EP2236605B1 (en) * 2007-12-28 2016-06-08 The Chemo-Sero-Therapeutic Research Institute Human anti-alpha 9 integrin antibody
CN102869776B (zh) * 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
WO2016149265A1 (en) 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
US10344071B2 (en) 2015-07-28 2019-07-09 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN114292899B (zh) * 2022-01-08 2024-03-26 安徽医科大学第一附属医院 一种肝细胞生长因子检测及信号增敏探针、引物对及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4683196A (en) 1983-12-12 1987-07-28 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5573933A (en) 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5922854A (en) 1991-06-14 1999-07-13 Kumar; Ramesh Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5316921A (en) 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
WO1993025071A1 (en) 1992-06-12 1993-12-23 Dnx Corporation Production of human hemoglobin in transgenic pigs
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0662130B1 (en) 1992-09-18 1997-11-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A method of producing hepatocyte growth factor and a cell line
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
US5714320A (en) 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE247716T1 (de) 1994-02-07 2003-09-15 Beckman Coulter Inc Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6143495A (en) 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
WO1997035033A1 (en) 1996-03-19 1997-09-25 Molecular Tool, Inc. Method for determining the nucleotide sequence of a polynucleotide
DE69739856D1 (de) 1996-07-03 2010-06-02 Genentech Inc Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
JP4642303B2 (ja) * 1999-09-21 2011-03-02 アンジェスＭｇ株式会社 脳血管障害のための遺伝子治療
EP1242451A2 (en) * 1999-12-15 2002-09-25 EntreMed, Inc. Compositions and methods for inhibiting endothelial cell proliferation
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2001083819A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
WO2002029087A2 (en) 2000-10-02 2002-04-11 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
CN1150035C (zh) * 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
ATE435303T1 (de) 2002-08-12 2009-07-15 New England Biolabs Inc Verfahren und zusammensetzungen in verbindung mit gen-silencing
DE10242663A1 (de) * 2002-09-13 2004-03-25 Forschungszentrum Karlsruhe Gmbh Verfahren zur Identifizierung von Inhibitoren in vivo
US20050026830A1 (en) * 2003-05-14 2005-02-03 Yasushi Kawaguchi Compositions and methods for treating fibrosis
WO2005023287A1 (ja) * 2003-09-03 2005-03-17 Kringle Pharma Inc. ヒト組換えｈｇｆを含有する皮膚潰瘍予防治癒剤
DE602005021272D1 (de) * 2004-03-31 2010-07-01 Anges Mg Inc Gentherapie mit Hepatozyten-Wachstumsfaktor zur Verbesserung des Überlebens von Muskel- und Hautgewebelappen
JP5313660B2 (ja) * 2005-03-31 2013-10-09 ザ ジェネラル ホスピタル コーポレイション Ｈｇｆ／ｈｇｆｒ活性の観察と調節
JP4111993B2 (ja) * 2006-05-29 2008-07-02 アンジェスＭｇ株式会社 リンパ管新生促進剤
JP2016031772A (ja) 2014-07-30 2016-03-07 株式会社日立ハイテクファインシステムズ 熱アシスト磁気ヘッド素子の検査方法及びその装置

Also Published As

Publication number Publication date
US20070010443A1 (en) 2007-01-11
PL1863519T3 (pl) 2014-03-31
TW200722099A (en) 2007-06-16
US20150030611A1 (en) 2015-01-29
JP4664441B2 (ja) 2011-04-06
US20100227821A1 (en) 2010-09-09
CN101189023B (zh) 2013-01-30
CN102989012B (zh) 2015-05-13
EP2674165A2 (en) 2013-12-18
JP5313660B2 (ja) 2013-10-09
CN102989012A (zh) 2013-03-27
JP2008538551A (ja) 2008-10-30
DK1863519T3 (da) 2014-01-13
JP5722960B2 (ja) 2015-05-27
TWI362940B (en) 2012-05-01
JP2012149087A (ja) 2012-08-09
US8865673B2 (en) 2014-10-21
EP1863519B1 (en) 2013-09-25
US20130064833A1 (en) 2013-03-14
JP2010265266A (ja) 2010-11-25
HK1183441A1 (en) 2013-12-27
ES2440953T3 (es) 2014-01-31
JP2013216690A (ja) 2013-10-24
EP2674165A3 (en) 2014-07-30
KR20130114763A (ko) 2013-10-18
JP2013136622A (ja) 2013-07-11
EP2674165B1 (en) 2016-10-12
KR20140068234A (ko) 2014-06-05
CN101189023A (zh) 2008-05-28
EP1863519A1 (en) 2007-12-12
WO2006105511A1 (en) 2006-10-05
JP5801835B2 (ja) 2015-10-28

Similar Documents

Publication Publication Date Title
US8865673B2 (en) Monitoring and modulating HGF/HGFR activity
JP2003528611A (ja) β様糖タンパク質ホルモンのポリペプチドおよびヘテロ二量体
US20090068102A1 (en) Treating stroke
EP3452512B1 (en) Methods and pharmaceutical compositions for the treatment of tissue lesions
KR101611322B1 (ko) 림프 기능을 증가시키는 방법
US20120076793A1 (en) Agent for promoting hepatic cell replication and agent for improving insulin resistance
HK1183441B (en) Monitoring and modulating hgf/hgfr activity
JP2008546716A (ja) 抗ＧＦＲα３抗体
CN100577212C (zh) E4bp4基因在胚胎着床过程中的功能及其应用
CN100391534C (zh) 平滑肌细胞增殖的调节
KR100883860B1 (ko) 에리스로포이에틴에 의해 수반되는 고혈압 방지를 위한조성물 및 방법
CN101124239A (zh) 调节排卵
Doll Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071026

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110329

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130227

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130726

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131025

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140127

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20131025

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101000477

Request date: 20140127

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140220

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140127

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130726

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20110329

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2014101000477; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20140127

Effective date: 20160819

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160819

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20140127

Decision date: 20160819

Appeal identifier: 2014101000477

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20160912

Patent event code: PE09021S02D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20161111

WITB Written withdrawal of application